Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | EVP Corp. Affairs, G.C., Sect. | September 14, 2022 | September 16, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RIGEL PHARMACEUTICALS INC
Report date September 14, 2022 · Filed September 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2029-01-23 | Direct | 81,250 |
Reported balance
After 2022-09-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-14 · Grant · Acquired 81,250 · Balance 81,250 F1: The reporting person was granted an option with a performance-based condition with respect to 81,250 shares of common stock on January 23, 2019. Thus, the exercise price of this option is $2.00 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On September 14, 2022, it was determined that the performance metric had been met. F2: The option was fully vested on September 14, 2022, the date the determination was made that the performance metric had been met. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person was granted an option with a performance-based condition with respect to 81,250 shares of common stock on January 23, 2019. Thus, the exercise price of this option is $2.00 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On September 14, 2022, it was determined that the performance metric had been met.
F2: The option was fully vested on September 14, 2022, the date the determination was made that the performance metric had been met.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2022 Filed Sep 16, 2022 20:15 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 81,250 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001140361-22-033613 · form4.xml · derivative · entry 1 VANCE DOLLY · CIK 0001237676 · EVP Corp. Affairs, G.C., Sect. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,250 Underlying: Common Stock · 81,250 shares Expires 2029-01-23 F1 · shares: The reporting person was granted an option with a performance-based condition with respect to 81,250 shares of common stock on January 23, 2019. Thus, the exercise price of this option is $2.00 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On September 14, 2022, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on September 14, 2022, the date the determination was made that the performance metric had been met. Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 01:42 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001567619-22-001778 · doc1.xml · derivative · entry 2 VANCE DOLLY · CIK 0001237676 · EVP Corp. Affairs, G.C., Sect. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-01-24 F3 · derivative.exercise_date: The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2022, subject to the reporting person's continuous service to the issuer through each such period. Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 01:42 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-001778 · doc1.xml · nonDerivative · entry 1 VANCE DOLLY · CIK 0001237676 · EVP Corp. Affairs, G.C., Sect. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,260 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from February 1, 2022, with the first annual vest occurring on February 1, 2023. F2 · balance_after: Includes 9,685 shares acquired under the Issuer's stock purchase plan. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 23:04 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 81,250 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001567619-21-019429 · doc1.xml · derivative · entry 1 VANCE DOLLY · CIK 0001237676 · EVP Corp. Affairs, G.C., Sect. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,250 Underlying: Common Stock · 81,250 shares Expires 2029-01-23 F1 · shares: The reporting person was granted a performance-based option to purchase 81,250 shares of common stock on January 23, 2019. Thus, the exercise price of this option is $2.00 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On November 4, 2021, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on October 25, 2021, the date the performance metric had been met. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:24 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001179110-21-004128 · edgar.xml · derivative · entry 1 VANCE DOLLY · CIK 0001237676 · EVP Corp. Affairs, G.C., Sect. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2030-02-06 F1 · shares: The reporting person was granted a performance-based option to purchase 37,500 shares of common stock on February 6, 2020. Thus, the exercise price of this option is $2.42 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On April 1, 2021, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on April 1, 2021, the date the performance metric had been met. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 23:51 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option(right to buy) · Derivative | 125,000 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001179110-21-000983 · edgar.xml · derivative · entry 1 VANCE DOLLY · CIK 0001237676 · EVP Corp. Affairs, G.C., Sect. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2021, subject to the reporting person's continuous service to the issuer through each such period. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:30 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001179110-20-001350 · edgar.xml · derivative · entry 1 VANCE DOLLY · CIK 0001237676 · EVP Corp. Affairs, G.C., Sect. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-02-06 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2020, subject to the reporting person's continuous service to the issuer through each such period. Read SEC document |
| November 18, 2019 Filed Nov 21, 2019 01:11 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001179110-19-011940 · edgar.xml · derivative · entry 1 VANCE DOLLY · CIK 0001237676 · EVP Corp. Affairs, G.C., Sect. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-01-24 F1 · derivative.exercise_date: The reporting person was granted a performance based option to purchase 75,000 shares of common stock on January 24, 2018. Thus,the exercise price of this option is $4.49 (the closing price of the issuer's common stock on Nasdaq the day prior to the date of grant). In light of the performance-based vesting condition of this grant, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 18, 2019, it was determined that the performance metric had been met. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 23:22 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001179110-19-004207 · edgar.xml · derivative · entry 1 VANCE DOLLY · CIK 0001237676 · EVP Corp. Affairs, G.C., Sect. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-01-24 F1 · derivative.exercise_date: On January 24, 2018, the reporting person was granted a performance based option to purchase 75,000 shares of common stock based on a specific performance metric. On March 20, 2019, it was determined that the performance metric had been met. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 23:20 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 162,500 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001179110-19-000932 · edgar.xml · derivative · entry 1 VANCE DOLLY · CIK 0001237676 · EVP Corp. Affairs, G.C., Sect. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 162,500 shares Expires 2029-01-23 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2019. Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:41 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001179110-18-006679 · edgar.xml · derivative · entry 1 VANCE DOLLY · CIK 0001237676 · EVP Corp. Affairs, G.C., Sect. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-02-02 F1 · derivative.exercise_date: On February 2, 2017 the reporting person was granted an option to purchase 150,000 shares of common stock. The option vested based on the Compensation Committee's determination that one or more pre-established performance conditions had been achieved. On May 9, 2018, the Compensation Committee determined that the performance conditions had been achieved, resulting in full vesting of the option. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 23:27 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001179110-18-001141 · edgar.xml · derivative · entry 1 VANCE DOLLY · CIK 0001237676 · EVP Corp. Affairs, G.C., Sect. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-01-24 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2018. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:55 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001179110-17-006154 · edgar.xml · derivative · entry 2 VANCE DOLLY · CIK 0001237676 · EVP Corp. Affairs, G.C., Sect. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2026-01-26 F2 · derivative.exercise_date: On January 26, 2016 the reporting person was granted an option to purchase 150,000 shares of common stock. The option vested based on the Compensation Committee's determination that one or more pre-established performance conditions had been achieved. On April 19, 2017, the Compensation Committee determined that the performance conditions had been achieved, resulting in full vesting of the option. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:55 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001179110-17-006154 · edgar.xml · derivative · entry 1 VANCE DOLLY · CIK 0001237676 · EVP Corp. Affairs, G.C., Sect. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2024-02-27 F1 · derivative.exercise_date: On February 27, 2014 the reporting person was granted an option to purchase 125,000 shares of common stock. The option vested based on the Compensation Committee's determination that one or more pre-established performance conditions had been achieved. As previously reported on April 4, 2016, the Compensation Committee determined that the performance condition had been achieved with respect to 62,500 shares of common stock. On April 19, 2017, the Compensation Committee determined that the performance conditions had been achieved with respect to the remaining 62,500 shares of common stock, resulting in full vesting of the option. Read SEC document |
| February 02, 2017 Filed Feb 7, 2017 00:23 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001179110-17-001816 · edgar.xml · derivative · entry 1 VANCE DOLLY · CIK 0001237676 · EVP Corp. Affairs, G.C., Sect. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-02-02 F1 · derivative.exercise_date: The shares vest monthly over four (4) years from January 1, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.